#3 - Gossamer Bio (NASDAQ:GOSS)
The small-cap sector is filled with biotech companies, and with good reason. Many of these are clinical-stage companies that lack earnings and, in many cases, revenue. These companies are working on drugs and therapeutics that will potentially be used to treat a range of diseases and other conditions.
Such is the case for Gossamer Bio (NASDAQ:GOSS). The company does not have a commercially available drug. But its lead candidate, seralutinib, is in stage 2 trials. Seralutinib, given the clinical name GB002, targets Pulmonary Arterial Hypertension (PAH). This condition has a five-year survival rate of approximately 55% with the current standard of care available.
Results from the stage 2 trial are expected by the end of 2022. An analyst from Wedbush forecasts that if the drug could capture 42% of the market and deliver $2.5 billion in revenue to Gossamer Bio if it launches, as forecast, in 2026.
Wedbush isn’t the only bullish analyst. In fact, GOSS stock has a Moderate Buy rating with a consensus price target of $19.60, a 58% upside from its current price.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Read More - Current Price
- $0.66
- Consensus Rating
- Buy
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $9.20 (1,284.3% Upside)
